Global Down Syndrome

Issue 2 of 4 - 2017

Issue link: http://viewer.e-digitaledition.com/i/842481

Contents of this Issue

Navigation

Page 9 of 31

SCIENCE SNPs EGCG: PROCEED WITH CAUTION Preliminary research on the green tea polyphenol epigallocatechin- 3-gallate (EGCG) suggests the compound may improve cognition in people with Down syndrome. However, scientists at Indiana University–Purdue University Indianapolis found no improvement in cognition in the Ts65Dn mouse model of Down syndrome, even when EGCG was given at various doses. Importantly, high doses led to detrimental side effects on the skeleton. Highly purified EGCG inhibited its target — the protein DYRK1A encoded on chromosome 21 — in the bones but not in the brain, which could explain its lack of efficacy. The findings point to the importance of identifying the dose of EGCG that could be beneficial in Down syndrome without having negative impacts, and of defining the possible contribution of other active compounds in green tea extract. Physiology & Behavior, MAY 2017 MORE RELIABLE VISION TESTS NEEDED FOR THOSE WITH DOWN SYNDROME Researchers from the University of Houston College of Optometry have found that autorefractor testing, an objective measure used to determine a person's prescription for glasses or contact lenses, is not always reliable when used for people with Down syndrome. They performed repeated autorefractor tests on 139 typical patients and patients with Down syndrome, ranging in age from 8 to 55, and found that the variation between those repeated tests was three times greater in patients with Down syndrome than in typical patients. The authors conclude that multiple methods for determining glasses prescriptions should be used for people with Down syndrome to ensure the best possible prescription to correct vision. Optometry and Vision Science, MAY 2017 DO HEALTH PROBLEMS COME FROM 'MISFOLDED' PROTEINS? Abnormal numbers of chromosomes, such as having three copies of chromosome 21 instead of two, which occurs in Down syndrome, could potentially overload the protein synthesis machinery, leading to the appearance of "misfolded" proteins. When present, misfolded proteins trigger a stress response, a phenomenon linked to Alzheimer's disease, and other conditions common among people with Down syndrome. Using cell samples and mouse models, researchers from the University of Colorado Denver and the Linda Crnic Institute for Down Syndrome have found evidence of protein misfolding in Down syndrome. Trisomic cells seem unable to adapt to misfolded proteins, which may explain the increased rates of certain conditions in this population. These results may lead to the development of targeted therapies to ameliorate the effects of protein misfolding. PLoS One, APRIL 2017 In 2013, he and his team made another exciting discovery: A single injection of a molecule called a sonic hedgehog agonist given to a Ts65Dn mouse at birth stimulated a signaling pathway in the brain to mitigate some of the negative cognitive characteristics associated with Down syndrome. "The molecule normalized growth of the cerebellum [which is usually smaller in people with Down syndrome], improved learning and memory, and normalized the way neurons in the hippocampus communicated with each other," Dr. Reeves said. "My lab is working to turn this molecule into a drug we could take into clinical trials." APPLIED SCIENCE Dr. Reeves' lab is now using his pioneering findings to make even greater headway into research that will benefit not only people with Down syndrome but the typical population as well. For instance, children with Down syndrome are at increased risk of being born with a heart abnormality called atrioventricular septal defect, which requires heart surgery. Dr. Reeves hopes to learn which genes are responsible for the development of heart defects by comparing DNA from families of children with both Down syndrome and a heart defect to DNA from families of children with Down syndrome and no heart defect. The lab is also using his research into the sonic hedgehog agonist as a basis for investigating which genes on chromosome 21 block the pathway rescued by the sonic hedgehog molecule, which specific regions of the brain are impacted and how, and whether other drugs might achieve the same effect. In collaboration with fellow researchers, Dr. Reeves is working to characterize the symptoms of and CONTINUED FROM PAGE 9 10 2017 ISSUE 2 OF 4 • DOWN SYNDROME WORLD

Articles in this issue

Archives of this issue

view archives of Global Down Syndrome - Issue 2 of 4 - 2017